Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Motor Imagery in Aphantasia

NCT06140940 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-03-28
Last updated
2025-07-24

Condition(s) studied

Aphasia

Investigational drug(s) / intervention(s)

High-definition transcranial direct current (HD-tDCS), active conditionHigh-definition transcranial direct current (HD-tDCS), sham condition

High-definition transcranial direct current (HD-tDCS), active condition: Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).

High-definition transcranial direct current (HD-tDCS), sham condition: Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).

Study summary

The present study aims to characterize and modulate motor imagery abilities in individuals with aphantasia. The investigators will characterize the neurophysiological and physiological underpinnings of mental imagery abilities in participants with aphantasia by investigating several indices of motor imagery abilities and comparing them to participants with typical mental imagery abilities. The investigators will investigate whether non-invasive brain stimulation applied to the primary motor cortex improves mental imagery abilities in participants with aphantasia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * For the aphantasia group only: congenital aphantasia defined as a life-long inability to generate mental imagery (confirmed by a total score of 32 or less on the VVIQ, which is the gold standard questionnaire for aphantasia) * For the no-aphantasia group only: typical mental imagery capacities (confirmed by a total score of more than 32 on the VVIQ) * Covered by public health insurance * Understanding the French language * Signed written informed consent after being informed about the study Exclusion Criteria: * Presence or history of a somatic, neurologic, or mental illness * Actual pain or musculoskeletal disorders at the upper limb * Having a regular musical activity (more than once a week) because of high manual dexterity * Contraindication for noninvasive brain stimulation including the presence of ferromagnetic or magnetic sensitive metal objects implanted in the head or in close proximity (e.g., brain stent, clip, cochlear implants, or stimulator) * Pregnancy (controlled by urine pregnancy test in females without reported contraception) * Active seizure disorder or history of seizures * Participants under curatorship/guardianship

Primary outcome measure(s)

  • Gains in motor performance following mental training — 2 times: immediately before tDCS (baseline) and immediately after tDCS
    Gains in motor performance following mental training combined with tDCS will be measured using a sequential finger tapping-task. Gains following training will be expressed as a percentage of the baseline performance.

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier le Vinatier Bron France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06140940 on ClinicalTrials.gov ↗ ← All trials in France